Anas Younes, Chief Medical Officer and Head of Haematology R&D at AstraZeneca, shared a post on LinkedIn:
“Conventional response assessments in blood cancer may not fully capture residual disease burden. Minimal residual disease (MRD) testing has emerged as a highly sensitive prognostic tool, enabling detection of small numbers of remaining cancer cells and providing deeper insight into treatment response.
Advances in technologies such as next-generation sequencing, combined with artificial intelligence, are enhancing our ability to interpret complex biological data and support more informed, data-driven clinical decisions across hematology.
I encourage you to read this latest What Science Can Do blog from my AstraZeneca colleagues Nicholas Durham and Anthony Mato on how MRD testing is helping advance hematology care.”
Other articles featuring Anas Younes on OncoDaily.